Pfizer gets early FTC clearance for Metsera acquisition

Pfizer Inc. (NYSE: PFE) announced that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its pending acquisition of Metsera (NASDAQ: MTSR).

The FTC clearance satisfies the regulatory review requirements for the previously announced acquisition. The original waiting period was set to expire on November 7.

The information is based on a press release statement from Pfizer.

You May Also Be Interested In

• Mineralys presents heart failure biomarker data for lorundrostat at ENDO 2026
• Jefferies Upgrades Banca Generali SpA (BGN:IM) to Buy
• Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination